biopharmaceutical news

biopharmaceutical News, Video News

Bahrain arm of US firm bags Tata Mundra supply deal
BUS10Business/Energy/InternationalBahrain arm of US firm bags Tata Mundra supply dealDubai, Sep 22 IANS The Bahrain arm of US engineering major RathGibson been awarded a crucial supply deal for India’s upcoming 4,000-MW Tata Mundra power project.Larsen and Toubro, one of the contractors of the $4.2-billion project, has awarded the contract to RathGibson, according to which the latter will supply titanium-welded tubing for condensers for the project.“RathGibson was awarded this project based upon our high-quality products, dedication to customer service, and cost-effectiveness,” Alfredo D’Souza, RathGibson’s regional director for the Middle East, said in a statement. The Tata Mundra project is being developed by Coastal Gujarat Power Ltd at the port city of Mundra in Gujarat. This ultra mega power project will establish India’s first 800 MW unit of the supercritical technology thermal power plant, which is likely to be the most energy-efficient, coal-based thermal power plant in the country.The project is expected to supply power to around 16 million domestic consumers, apart from supplying cost competitive power to industry and agriculture, in Gujarat, Rajasthan, Maharashtra, Haryana and Punjab. The first of the power plant’s five 800 MW units is expected to be commissioned in July 2011, and the remaining units will be commissioned at subsequent intervals of four months each.RathGibson is a worldwide manufacturer of highly engineered stainless steel, nickel, and titanium tubing for diverse industries such as chemical, petrochemical, power generation, energy, oil and gas, food, beverage, pharmaceutical, biopharmaceutical, healthcare and biotechnology. --Indo-Asian News Serviceab/ank/jg261 Words22091527
2008-09-22 06:05:07
Cell Therapeutics to Raise Stock Price Via 1-for-10 Reverse Stock Split - Update
Biopharmaceutical company Cell Therapeutics, Inc. CTIC on Monday said that its Board of Directors has authorized a 1-for-10 reverse split of its common stock, which will become effective on August 31,...
2008-08-25 22:00:00
Altus' Late-Stage Trial Shows Trizytek Improved Fat Absorption in Cystic Fibrosis Patients with Pancreatic Insufficiency
Altus Pharmaceuticals Inc. ALTU on Monday said its Phase 3 efficacy trial of Trizytek, or porcine-free enzymes, in cystic fibrosis patients having pancreatic insufficiency met its primary endpoint of ...
2008-08-12 22:00:00
Isle biotech firm lands $5.1M grant
PanThera Biopharma LLC, an &aposAiea company developing biopharmaceuticals, has been awarded $5.1 million more in potential funding for its work developing an anti-toxin that can be used in combat...
2008-08-12 17:25:50
Genelabs Reports Results for the Second Quarter and First Six...
GNLB , a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases, reported financial results for the second quarter and six months ended Jun...
2008-08-12 15:00:00
Breathe in: Biotechs go inhalable route in battling nicotine addiction
A Colorado biotech company has won a federal grant to develop an inhalable version of a vaccine that Nabi Biopharmaceuticals is developing to battle nicotine addiction. ...
2008-08-09 12:08:32
Shape, like size, impacts emerging nano-medicine therapies' efficacy
Washington, August 6 ANI: Nanotechnology researchers at the University of North Carolina at Chapel Hill have discovered that tiny particles behave differently within cells depending upon their shapes, sizes, and surface chemistry. Published in the online edition of the journal PNAS, their findings may be helpful in developing effective nanomedicines for cancer. Dr. Joseph DeSimone, Chancellor's Eminent Professor of Chemistry in UNC's College of Arts and Sciences, has revealed that his research team used a special technique to make particles with specific shapes, sizes, and surface charges for their study.He said that their purpose was to optimise particle attributes for specific therapeutic objectives."This would mean that we could deliver lower dosages of drugs to specific cells and tissues in the body and actually be more effective in treating the cancer," he said.Having created particles of different dimensions, he added, the group changed one variable at a time, and experimented with different surface chemistries. Dr. DeSimone says that the different particles were later incubated with human cervical carcinoma epithelial HeLa cells, and the group monitored each type to see which ones the cells absorbed most effectively.He said that the long, rod-shaped particles were found to be internalised by cells about four times faster than lower aspect ratio particles.Such particles also travelled significantly further into the cell, he added. Stephanie Gratton, a graduate student in DeSimone's lab, said that the same phenomenon is found in natural organisms. "If we can design particles that rely on the same mechanisms that nature has perfected for bacteria, we may unlock the key for delivering therapeutics more efficiently and effectively to treat and cure disease," she said. Liquidia Technologies, a UNC spin-off company, is developing engineered nanoparticles for delivery of nucleic acids and small molecule therapeutics.The company's chief executive officer, Neal Fowler, said that the new findings could prove of interest to the biopharmaceutical industry."We are delighted to contribute to the important work that Professor DeSimone and his students are undertaking in the field of nanomedicine. This work answers key questions about the role of particle shape and size that industry leaders have been asking for some time," Fowler said. ANI
2008-08-06 04:00:00
Suven Life Presents Key Biology Pre-clinical Data For SUVN-520 At Chicago, Boston Conferences
Monday, Suven Life Sciences Ltd., a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, announced that it has presented key biology pre-clin...
2008-08-04 13:31:10
Biocon: Hold
Lack of near-term catalysts, staid growth in biopharmaceuticals over 80 per cent of sales and sluggish performance in contract research services have dulled the earnings picture for biotechnology com...
2008-08-02 19:23:16

Explore the Worldviewer.com Network Sites

Bahrain arm of US firm bags Tata Mundra supply deal

Cell Therapeutics to Raise Stock Price Via 1-for-10 Reverse Stock Split - Update

Altus' Late-Stage Trial Shows Trizytek Improved Fat Absorption in Cystic Fibrosis Patients with Pancreatic Insufficiency

Isle biotech firm lands $5.1M grant

Genelabs Reports Results for the Second Quarter and First Six...

Breathe in: Biotechs go inhalable route in battling nicotine addiction

Shape, like size, impacts emerging nano-medicine therapies' efficacy

Suven Life Presents Key Biology Pre-clinical Data For SUVN-520 At Chicago, Boston Conferences

Biocon: Hold